來源: MarketWatch ↗
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
|
暫時無法翻譯，請重試。
來源報導重點
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
在 MarketWatch 閱讀原始報導 ↗